TY - JOUR
T1 - Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci
AU - Munita, Jose M.
AU - Murray, Barbara E.
AU - Arias, Cesar A.
N1 - Funding Information:
Funding: CAA was supported by the National Institutes of Health (NIH) through grant R01 AI093749 from the National Institute of Allergy and Infectious Diseases (NIAID). BEM was supported in part by NIH R01 AI047923. JMM was supported in part by a grant provided by the Chilean Ministry of Education and by a grant from Clínica Alemana de Santiago and Universidad del Desarrollo (Chile).
Publisher Copyright:
© 2014 Elsevier B.V. and the International Society of Chemotherapy.
PY - 2014/9/2
Y1 - 2014/9/2
N2 - Treatment of severe infections caused by vancomycin-resistant enterococci (VRE) is challenging due to the scarcity of reliable therapeutic alternatives. In this context, daptomycin (DAP), a lipopeptide antibiotic, has emerged as an interesting alternative as it is one of the few compounds that retain in vitro bactericidal activity against VRE isolates, although it has not been approved for this purpose by regulatory agencies. In this review, we will summarise the clinical, animal and in vitro evidence evaluating the efficacy of DAP for the management of deep-seated VRE infections. In addition, we will address important clinical concerns such as the emergence of DAP resistance during therapy and reports of therapeutic failure with DAP monotherapy. Finally, we will discuss possible future strategies (such as the use of higher doses and/or combination therapies) to optimise the use of this antibiotic against VRE.
AB - Treatment of severe infections caused by vancomycin-resistant enterococci (VRE) is challenging due to the scarcity of reliable therapeutic alternatives. In this context, daptomycin (DAP), a lipopeptide antibiotic, has emerged as an interesting alternative as it is one of the few compounds that retain in vitro bactericidal activity against VRE isolates, although it has not been approved for this purpose by regulatory agencies. In this review, we will summarise the clinical, animal and in vitro evidence evaluating the efficacy of DAP for the management of deep-seated VRE infections. In addition, we will address important clinical concerns such as the emergence of DAP resistance during therapy and reports of therapeutic failure with DAP monotherapy. Finally, we will discuss possible future strategies (such as the use of higher doses and/or combination therapies) to optimise the use of this antibiotic against VRE.
KW - Daptomycin
KW - Enterococcal bacteraemia
KW - Enterococci
KW - VRE
UR - http://www.scopus.com/inward/record.url?scp=84908448459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908448459&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2014.08.002
DO - 10.1016/j.ijantimicag.2014.08.002
M3 - Review article
C2 - 25261158
AN - SCOPUS:84908448459
SN - 0924-8579
VL - 44
SP - 387
EP - 395
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 5
ER -